v3 Template
I

ImpriMed

Veterinary Healthcare and Biotechnology ~820 employees
Founded
--
Employees (Est.)
~820
41 leaders known
Total Funding
$23.0M
Funding Rounds
1
Last Funding
2023-12-19

About ImpriMed

ImpriMed is a company focused on personalized cancer treatment for dogs and cats, specializing in lymphoma and leukemia. They use artificial intelligence and comprehensive analysis of live cancer cells to predict the most effective chemotherapy drugs for individual pets, aiming to optimize treatment outcomes and save time and costs for pet owners and veterinarians.

Products & Services

Personalized Prediction Profile:AI-driven drug response predictions for canine lymphoma and leukemia, including flow cytometry and PARR.
Drug Response Predictions:Personalized anticancer drug treatment decisions for canines, recently introduced.
Flow Cytometry:Determines lymphoma or leukemia subtypes accurately for canines and felines.
PARR:Detects neoplastic B-cell or T-cell clones in canines and felines.
Multidrug Sensitivity Genotyping (MDR1):Identifies MDR1 carrier status in canines.

Specialties

Artificial Intelligence in Veterinary Medicine Personalized Cancer Treatment Canine and Feline Lymphoma and Leukemia Diagnostics Drug Response Predictions Flow Cytometry and PARR Testing

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Series A
T: -
FT: Series A 		A: 23000000
MR: -
FA: 23 million
FAN: 23000000 		D: 2023-12-19
FD: 2023-12-19 		8 investors
Series A Latest
2023-12-19
$23.0M
8 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

S

Sungwon Lim

Co-Founder & CEO, Board Director

LinkedIn (Pro only)
J

Jamin Koo

Co-Founder & CTO Board Director

LinkedIn (Pro only)
V

Valerie Goodwin-Adams

Chief Commercial Officer

LinkedIn (Pro only)
M

Mary Frye

Vice President, Commercial Operations

I

Ilona Holcomb

Director, Bioscience

J

Josephine Tsang

Research Scientist

View 38 more team members with Pro

Unlock Full Team Directory

Recent News

ImpriMed Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Veterinary Healthcare and Biotechnology
Company Size
~820 employees (est.)

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro